Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 75/100

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

Tuesday, September 26, 2023 2 min read
Key Takeaway: REGENXBIO Inc. has announced that it will present at the 28th Annual Congress of the World Muscle Society in Charleston, SC, from October 3-7, 2023. The presentations will include interim data from the Phase I/II AFFINITY DUCHENNE trial, highlighting safety and microdystrophin protein levels over three months. Senior Director Jahannaz Dastgir and Dr. Aravindhan Veerapandiyan will lead the discussions on the investigational gene therapy for Duchenne muscular dystrophy. A conference call is scheduled for October 3, 2023, to provide further details on the interim data.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of interim data from the Phase I/II AFFINITY DUCHENNE trial.
  • Inclusion of data on longer-term safety and microdystrophin protein expression levels.
  • Renewed focus on gene therapy for Duchenne muscular dystrophy.

Full Press Release Details

ROCKVILLE, Md., Sept. 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in Charleston, SC from October 3-7, 2023. Presentations include interim data from the Phase I/II AFFINITY DUCHENNE™ trial, including longer-term safety and initial microdystrophin protein expression levels in muscle at three months.
The presentations will be presented as follows:
Abstract Title: An investigational AAV8 gene therapy coding for a novel microdystrophin as a treatment for Duchenne muscular dystrophy (P16)
Presenter: Jahannaz Dastgir, DO, Senior Director, Clinical Development, REGENXBIO
Abstract Title: RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: interim clinical data (LBP19)
Presenter: Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital
REGENXBIO will host a conference call on Tuesday, October 3, 2023 starting at 4:30 PM ET to review the interim data being presented in greater detail. Instructions for joining the call will be available in the data release and on the Investors section of REGENXBIO's website at www.regenxbio.com.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Corporate Communications
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

What is the focus of REGENXBIO's upcoming presentations?

REGENXBIO will present interim data from the Phase I/II AFFINITY DUCHENNE™ trial.

Who will present the AAV8 gene therapy data at the World Muscle Society?

Jahannaz Dastgir, DO, will present on the novel microdystrophin treatment.

When is the REGENXBIO conference call scheduled?

The conference call is on October 3, 2023, at 4:30 PM ET.

What technology does REGENXBIO utilize for gene delivery?

REGENXBIO uses its NAV Technology Platform for gene delivery via AAV vectors.

What are REGENXBIO's future goals for its AAV Therapeutics?

REGENXBIO aims to advance five AAV Therapeutics to pivotal or commercial stages by 2025.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO Duchenne muscular dystrophy gene therapy World Muscle Society interim data
Last updated: Sep 26, 2023